Skip to main
STAA

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 25%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 13%

Bulls say

Staar Surgical is a company with a positive outlook for several reasons. Firstly, the company has a dominant market position in phakic IOLs, which are used in refractive surgery and make up almost all of Staar Surgical's revenue. Secondly, the company has shown strong growth potential in China, with a 111% increase in net sales and a 21.4% margin in the second quarter of 2026. This growth is expected to continue with the appointment of a permanent CEO and the resolution of distributor disruptions. Lastly, the company has a solid financial position, with a debt-free balance sheet and a positive outlook for profitability in the future.

Bears say

Staar Surgical is facing potential market share loss in the near term due to competitors entering the market with toric lenses, creating a technology gap. However, the company has built a strong brand equity among patients in China, which may offset some of the competition. With the potential for market share ramp by competitors after patient outcome assessments, it is important for analysts to monitor the company's performance closely. As of fiscal year 2020, the company had a strong financial position with a cash and cash equivalents balance of $147.7 million and a net income of $22 million.

STAAR Surgical (STAA) has been analyzed by 8 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Hold based on their latest research and market trends.

According to 8 analysts, STAAR Surgical (STAA) has a Hold consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.